首页> 外文期刊>British Journal of Pharmacology >Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease.
【24h】

Increased response to big endothelin-1 in atherosclerotic human coronary artery: functional evidence for up-regulation of endothelin-converting enzyme activity in disease.

机译:动脉粥样硬化性人类冠状动脉中对大内皮素1的反应增加:疾病中内皮素转化酶活性上调的功能证据。

获取原文
获取原文并翻译 | 示例
       

摘要

Overproduction of the potent vasoconstrictor peptide endothelin-1 (ET-1) is implicated in the pathogenesis of coronary artery disease. In endothelium-denuded human coronary arteries the response to big ET-1 was significantly enhanced in atherosclerotic arteries (coronary artery disease, CAD; n=7) with an EC50 value of 96 nM (57- 161 nM, 95% C.I.) compared to 274 nM (205-365 nM) in non-diseased arteries (dilated cardiomyopathy, DCM; n=10) (Mann-Whitney U-test, P<0.05). Higher levels of immunoreactive endothelin (ET) could be detected by radioimmunoassay in bathing medium taken from CAD arteries than from DCM arteries (2.8+/-0.5 nM, n=5 vs 1.1+/-0.2 nM, n=7) (Student's two-tailed t-test, P<0.05). There were no differences in responses of arteries from either group to ET-1 (EC50 10 nM, CAD vs 14 nM, DCM). The enhanced response of atherosclerotic human coronary arteries to big ET-1 appears to be due to up-regulation of endothelin-converting enzyme (ECE) activity rather than to an augmented response of the arteries to ET-1. This non-endothelial ECE may therefore be an important therapeutic target in coronary artery disease.
机译:有效的血管收缩肽内皮素-1(ET-1)的过量生产与冠状动脉疾病的发病机理有关。在内皮剥夺的人冠状动脉中,对大ET-1的反应在动脉粥样硬化性动脉(冠状动脉疾病,CAD; n = 7)中得到显着增强,EC50值为96 nM(57-161 nM,95%CI)。未患病的动脉中为274 nM(205-365 nM)(扩张型心肌病,DCM; n = 10)(Mann-Whitney U检验,P <0.05)。通过放射免疫分析,在取自CAD动脉的沐浴介质中检测到的免疫反应内皮素(ET)的水平高于从DCM动脉中获得的(2.8 +/- 0.5 nM,n = 5对1.1 +/- 0.2 nM,n = 7)(学生的两个尾t检验,P <0.05)。两组患者对ET-1的动脉反应均无差异(EC50为10 nM,CAD vs 14 nM,DCM)。动脉粥样硬化性人冠状动脉对大ET-1的增强反应似乎是由于内皮素转化酶(ECE)活性上调,而不是由于动脉对ET-1增强了反应。因此,这种非内皮ECE可能是冠状动脉疾病的重要治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号